Cognitive and adaptive advantages of growth hormone treatment in children with Prader-Willi syndrome
- PMID: 27481444
- PMCID: PMC5161611
- DOI: 10.1111/jcpp.12601
Cognitive and adaptive advantages of growth hormone treatment in children with Prader-Willi syndrome
Abstract
Background: People with Prader-Willi syndrome (PWS) typically have mild to moderate intellectual deficits, compulsivity, hyperphagia, obesity, and growth hormone deficiencies. Growth hormone treatment (GHT) in PWS has well-established salutatory effects on linear growth and body composition, yet cognitive benefits of GHT, seen in other patient groups, have not been well studied in PWS.
Methods: Study 1 included 96 children and youth with PWS aged 4-21 years who naturalistically varied in their exposures to GHT. Controlling for socioeconomic status, analyses compared cognitive and adaptive behavior test scores across age-matched treatment naïve versus growth hormone treated children. Study II assessed if age of treatment initiation or treatment duration was associated with subsequent cognition or adaptive behavior in 127, 4- to 21-year olds with PWS. Study III longitudinally examined cognitive and adaptive behavior in 168 participants who were either consistently on versus off GHT for up to 4-5 years.
Results: Compared to the treatment naïve group, children receiving GHT had significantly higher Verbal and Composite IQs, and adaptive communication and daily living skills. Children who began treatment before 12 months of age had higher Nonverbal and Composite IQs than children who began treatment between 1 and 5 years of age. Longitudinally, the groups differed in their intercepts, but not slopes, with each group showing stable IQ and adaptive behavior scores over time.
Conclusions: Cognitive and adaptive advantages should be considered an ancillary benefit and additional justification for GHT in people with PWS. Future efforts need to target apparent socioeconomic inequities in accessing GHT in the PWS population.
Keywords: Prader-Willi syndrome; adaptive behavior; cognition; growth hormone treatment.
© 2016 Association for Child and Adolescent Mental Health.
Conflict of interest statement
No conflicts declared.
Figures


Similar articles
-
Impact of genetic subtypes of Prader-Willi syndrome with growth hormone therapy on intelligence and body mass index.Am J Med Genet A. 2019 Sep;179(9):1826-1835. doi: 10.1002/ajmg.a.61293. Epub 2019 Jul 16. Am J Med Genet A. 2019. PMID: 31313492 Free PMC article.
-
Low dose growth hormone treatment in infants and toddlers with Prader-Willi syndrome is comparable to higher dosage regimens.Growth Horm IGF Res. 2017 Jun;34:1-7. doi: 10.1016/j.ghir.2017.03.001. Epub 2017 Mar 24. Growth Horm IGF Res. 2017. PMID: 28427039
-
Effects of growth hormone therapy on glucose metabolism and insulin sensitivity indices in prepubertal children with Prader-Willi syndrome.Horm Res. 2007;68(2):83-90. doi: 10.1159/000100371. Epub 2007 Feb 28. Horm Res. 2007. PMID: 17337902
-
Growth Hormone Treatment for Adults With Prader-Willi Syndrome: A Meta-Analysis.J Clin Endocrinol Metab. 2021 Sep 27;106(10):3068-3091. doi: 10.1210/clinem/dgab406. J Clin Endocrinol Metab. 2021. PMID: 34105729 Free PMC article.
-
Early psychomotor development and growth hormone therapy in children with Prader-Willi syndrome: a review.Eur J Pediatr. 2024 Mar;183(3):1021-1036. doi: 10.1007/s00431-023-05327-z. Epub 2023 Nov 21. Eur J Pediatr. 2024. PMID: 37987848 Review.
Cited by
-
The Effects of Growth Hormone Treatment Beyond Growth Promotion in Patients with Genetic Syndromes: A Systematic Review of the Literature.Int J Mol Sci. 2024 Sep 22;25(18):10169. doi: 10.3390/ijms251810169. Int J Mol Sci. 2024. PMID: 39337654 Free PMC article.
-
Biological, Behavioral, and Ethical Considerations of Prader-Willi Syndrome: A Primer for Behavior Analysts.Behav Anal Pract. 2021 Jul 8;15(2):562-570. doi: 10.1007/s40617-021-00618-z. eCollection 2022 Jun. Behav Anal Pract. 2021. PMID: 35692531 Free PMC article. Review.
-
Epigenetic therapy of Prader-Willi syndrome.Transl Res. 2019 Jun;208:105-118. doi: 10.1016/j.trsl.2019.02.012. Epub 2019 Mar 5. Transl Res. 2019. PMID: 30904443 Free PMC article. Review.
-
SNORD116 and growth hormone therapy impact IGFBP7 in Prader-Willi syndrome.Genet Med. 2021 Sep;23(9):1664-1672. doi: 10.1038/s41436-021-01185-y. Epub 2021 May 26. Genet Med. 2021. PMID: 34040195 Free PMC article.
-
Close yet so far away: a look into the management strategies of genetic imprinting disorders.Am J Stem Cells. 2018 Oct 1;7(4):72-81. eCollection 2018. Am J Stem Cells. 2018. PMID: 30510842 Free PMC article. Review.
References
-
- Bakker NE, Siemensma EP, van Rijn M, Festen DA, Hokken-Koelega AC. Beneficial effect of growth hormone treatment on health-related quality of life in children with Prader-Willi syndrome: A randomized controlled trial and longitudinal study. Hormone Research in Paediatrics. 2015;84:231–239. - PubMed
-
- Bertella L, Mori I, Grugni G, Pignatti R, Ceriani F, Molinari F, et al. Quality of life and psychological well-being in GH-treated, adult PWS patients: a longitudinal study. Journal of Intellect Disability Research. 2007;51:302–311. - PubMed
-
- Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: Comparisons to mental retardation. Journal of Autism and Developmental Disorders. 2000;30:237–243. - PubMed
-
- Boer H, Holland A, Whittington J, Butler J, Webb T, Clarke D. Psychotic illness in people with PWS due to chromosome 15 maternal uniparental disomy. Lancet. 2002;359:135. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical